Atria Investments Inc Has $7.91 Million Stock Holdings in Stryker Corporation $SYK

Atria Investments Inc lessened its stake in shares of Stryker Corporation (NYSE:SYK) by 7.7% in the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 22,492 shares of the medical technology company’s stock after selling 1,873 shares during the quarter. Atria Investments Inc’s holdings in Stryker were worth $7,905,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. United Financial Planning Group LLC acquired a new stake in shares of Stryker during the 3rd quarter worth about $27,000. CGC Financial Services LLC bought a new position in Stryker during the fourth quarter worth about $29,000. Strive Asset Management LLC acquired a new stake in Stryker in the 3rd quarter worth about $30,000. ANTIPODES PARTNERS Ltd acquired a new stake in Stryker in the 3rd quarter worth about $34,000. Finally, Copia Wealth Management raised its stake in Stryker by 181.6% in the 3rd quarter. Copia Wealth Management now owns 107 shares of the medical technology company’s stock worth $40,000 after purchasing an additional 69 shares in the last quarter. Institutional investors and hedge funds own 77.09% of the company’s stock.

Stryker Stock Up 0.4%

Shares of NYSE SYK opened at $306.74 on Friday. The company has a market capitalization of $117.59 billion, a P/E ratio of 35.50, a price-to-earnings-growth ratio of 1.92 and a beta of 0.80. Stryker Corporation has a 52-week low of $281.00 and a 52-week high of $404.87. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.25 and a current ratio of 2.11. The company’s 50 day moving average price is $329.68 and its 200-day moving average price is $351.73.

Stryker (NYSE:SYK) last issued its quarterly earnings results on Thursday, April 30th. The medical technology company reported $2.60 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). The firm had revenue of $6.02 billion during the quarter, compared to analyst estimates of $6.34 billion. Stryker had a return on equity of 23.42% and a net margin of 13.20%.The firm’s revenue for the quarter was up 2.6% on a year-over-year basis. During the same quarter last year, the firm posted $2.84 EPS. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Equities analysts forecast that Stryker Corporation will post 14.98 earnings per share for the current year.

Stryker Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Tuesday, June 30th will be given a $0.88 dividend. The ex-dividend date is Tuesday, June 30th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.1%. Stryker’s payout ratio is 40.74%.

Insider Activity

In other news, VP M Kathryn Fink sold 5,220 shares of the business’s stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $283.85, for a total value of $1,481,697.00. Following the transaction, the vice president owned 13,137 shares in the company, valued at approximately $3,728,937.45. The trade was a 28.44% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 4.60% of the company’s stock.

Analyst Ratings Changes

Several brokerages have weighed in on SYK. TD Cowen cut shares of Stryker from a “buy” rating to a “hold” rating and set a $387.00 price objective for the company. in a research note on Monday, January 26th. UBS Group dropped their price objective on shares of Stryker from $400.00 to $380.00 and set a “neutral” rating for the company in a research note on Tuesday, March 17th. BTIG Research decreased their target price on shares of Stryker from $397.00 to $379.00 and set a “buy” rating on the stock in a report on Friday, May 1st. Wells Fargo & Company decreased their target price on shares of Stryker from $456.00 to $418.00 and set an “overweight” rating on the stock in a report on Friday, May 1st. Finally, JPMorgan Chase & Co. decreased their target price on shares of Stryker from $445.00 to $400.00 and set an “overweight” rating on the stock in a report on Friday, May 1st. Sixteen research analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $395.48.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.